Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study

Inclusion Criteria: * Primary diagnosis: Current evidence of symptomatic GERD/NERD that comply with the Montreal definition of GERD/Nonerosive Esophageal Reflux Disease (NERD). GERD is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications. The concept of NERD is preserved in the typical reflux syndrome without esophageal injury, while reflux esophagitis falls under the category of esophageal syndromes with esophageal injury. * GERD status: patients will be recruited by the Investigator from out-patient clinics, hospital database or those who respond to the advertising. Patients must have a GERD history of frequent episodes of GERD-related symptoms during the last 3 months, and must have had troublesome heartburn and/or regurgitation of at least moderate intensity on at least 4 days during the week before the start of screening. * Patients must be sufficiently literate to be able to complete the RDQ unaided. Exclusion Criteria: * Patients who have a history of drug, solvent or alcohol abuse (weekly alcohol intake ≥ 140g). * Patients who have suffered cardiac chest pain within the last year. * Patients who have suffered a recent, significant unexplained weight loss of more than 6 kg in the last 6 months. * Female patients of childbearing potential who, for the duration of the study, are either unwilling or unable to take adequate contraceptive precautions or are unwilling to be sexually abstinent. * Pregnancy or lactating mother. * Patients with a history and/or symptom profile suggestive of the following: any other gastrointestinal (GI) disease (e.g. gastric or duodenal erosions and polyps larger than 0.5 cm), erosive GERD (Los Angeles \[LA\] classification grades C-D), Barrett's esophagus, peptic ulcer and/or ulcer complications, Zollinger-Ellison syndrome, gastric carcinoma, pyloric stenosis, oesophageal or gastric surgery, intestinal obstruction, current pernicious anaemia, indication for H-pylori eradication, hiatal hernias greater than 3 cm, known gastro-intestinal bleeding (hematochezia or hematemesis) within the last 3 months, and severe diseases of other major body systems. * Patients who have taken anti-cholinesterase drugs, traditional Chinese medicines for treating gastrointestinal disease, Ulcermin or misoprostol preparations within 7 days prior to screening or throughout the study. * Patients who have taken Proton Pump Inhibitors (PPIs) during the 10 days prior to screening, prokinetics or H2 antagonists during the 5 days prior to screening, or systemic glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs except low dose aspirin given for cardioprotection) on more than 3 consecutive days during the last 28 days prior to screening or PPI-based triple or quadruple therapy for eradication of H-pylori during the last 28 days prior to screening and throughout the study. * Patients who have taken any antacids within 24 hours before randomisation (Visit 2) and are unwilling or unable to withhold from taking them for the duration of the study. * Patients taking mucous membrane protection drugs or motility stimulants within the 5 days prior to screening and are unwilling or unable to withhold from taking them for the duration of the study. * Patients with difficulty in swallowing. * Patients with known hypophosphataemia, phenylketonuria or hypercalcaemia. * Patients with severe constipation, or history of intestinal obstruction. * In the opinion of the Investigator, patients with insufficient heart or kidney function and patients who require a low sodium diet. * Patients with any co-existing condition which, in the opinion of the Investigator, would be likely to compromise patient safety or interfere with assessment of efficacy. * Patients with any clinically significant abnormal laboratory values. * Patients with severe/impaired renal function or insufficiency. * Any previous history of allergy or known intolerance to any of the formulation constituents. * Relevant clinically significant abnormalities in the physical examination, ECG and safety analysis. * Previously randomised into the study. * Employee at study site. * Partner or first-degree relative (e.g. parents, siblings or children) of the Investigator. * Participation in a clinical study in the previous 6 months. * Unable in the opinion of the Investigator to comply fully with the study requirements. * Patients taking or requiring to take macrolide antibiotics, such as erythromycin, azithromycin, from the day before screening * Patients who failed screening will not be allowed to re-enter the study